

ECS Botanics Holdings Ltd (ASX:ECS)



ASX Announcement

27 July 2026

ECS Expands OzSun Portfolio with All-In-One Vape Range

Highlights:

- Two 2g OzSun all-in-one rosin blend inhalation products scheduled for Australian launch in mid-August 2026
- Vapes are the second-largest cannabis product category by sales in the US and third-largest in Canada, demonstrating the format's established position in mature North American legal cannabis markets
- Range expands ECS's higher-margin branded B2C portfolio, with expected gross margins broadly consistent with the AVANI portfolio
- Products supplied by Canadian GMP-licensed manufacturer Ichor Inc under a capital-efficient consignment arrangement, with no material capital expenditure required
- Larger 2g format is intended to provide competitive value per gram relative to the 1g format prevalent in the Australian market
- Rechargeable, inhalation-activated format integrates the battery, reservoir, ceramic heating core and mouthpiece, removing the need for a separate 510-thread battery

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis company, is pleased to announce the planned launch of two 2g all-in-one rosin blend inhalation products under its OzSun brand in mid-August 2026.

The range will expand ECS's higher-margin branded B2C portfolio into a larger-format, integrated vape product and will be supplied by Canadian GMP-licensed medicinal cannabis manufacturer Ichor Inc under an executed consignment agreement.

The initial products have been manufactured and are undergoing final packaging ahead of shipment to Australia. The required Australian import approvals have been obtained, with the planned launch subject to completion of packaging, importation and customary release-for-supply procedures.

OzSun Day and Night formulations

The initial range will comprise two tri-blend formulations aligned with the existing OzSun Day and Night product architecture.



Each formulation combines three cannabinoids, with CBG included in the Day formulation and CBN included in the Night formulation. The products use rosin blend formulations combining rosin and distillate, with native cannabis terpenes incorporated into the final formulation.

The formulations have been developed without making specific therapeutic claims and will be supplied within Australia's existing prescription medicinal cannabis framework.

Each product contains 2g of formulation with the rosin and distillate blend manufactured in Canada, with native terpenes incorporated into the formulation.



Image: All-in-one vapes with branding removed

Integrated rechargeable format

The all-in-one format combines the reservoir, battery, heating system and mouthpiece within a single inhalation-activated unit. The device is rechargeable through a USB-C port and uses a proprietary ceramic heating core. This removes the need for a separate battery device required by traditional 510-thread cartridges and provides a self-contained format that is ready for use following dispensing.

At 2g, the OzSun products will provide twice the fill volume of the 1g format currently prevalent in the Australian medicinal cannabis vape category. The larger format is intended to provide competitive value per gram and differentiate OzSun within the existing product market.

Capital-efficient commercial model

The products will be supplied under a consignment arrangement with Ichor, under which the majority of the product cost becomes payable as inventory is sold. The consignment structure provides ECS with a capital-efficient pathway to establish demand before scaling subsequent orders.

Based on current proposed pricing and landed product costs, ECS expects the range to generate gross margins broadly consistent with the Company's higher-margin AVANI branded products.



Market context

Vape products have become an established category across mature North American cannabis markets.

BDSA retail sales data for the 12 months to May 2026 indicates that vapes represented approximately 26% of total US legal cannabis retail sales and generated approximately US\$8 billion in category revenue, increasing by 6% from the prior corresponding period¹.

Within the category, disposable vape sales increased by 41%, with BDSA identifying the growth of larger-format 2g products as an important driver of value and category development.

Although ECS has not used the North American data as a forecast of Australian demand, the Company considers the category's development supportive of the strategic rationale for adding a larger-format, integrated vape product to the OzSun portfolio.

ECS Botanics Managing Director, Nan-Maree Schoerie, said:

"The OzSun 2g all-in-one range gives ECS a differentiated product in an established international category, combining a larger, value-oriented format with the simplicity of an integrated rechargeable device."

"The consignment structure limits the upfront working capital required and does not involve material capital expenditure, while expected margins are consistent with our higher-margin AVANI products."

"This is a disciplined extension of the ECS branded portfolio and another opportunity to extract greater value from the commercial platform and distribution capabilities the Company has already established."

Launch and outlook

The OzSun all-in-one range is scheduled to launch in mid-August 2026 through ECS's existing Australian medicinal cannabis distribution channels, supported by the Company's Medical Science Liaison engagement with healthcare professionals. ECS will monitor initial sales and product uptake before determining the timing and scale of subsequent orders.

The Company expects the new range to support continued growth and diversification of its branded B2C portfolio. Further updates will be provided where sales performance, additional product launches or expansion of the range become material.

Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

Investors and Media

Tim Dohrmann, NWR Communications

P: +61 468 420 846

E: tim@nwrcommunications.com.au

About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.

¹ BDSA, *The Top 10 Vape Brands in Cannabis*, based on retail sales tracking data for June 2025 to May 2026.